Search results for "Platelet"

showing 10 items of 786 documents

HIF-1α and HIF-2α Are Differentially Regulated In vivo in Neuroblastoma: High HIF-1α Correlates Negatively to Advanced Clinical Stage and Tumor Vascu…

2009

Abstract Purpose: Hypoxia is considered to be a major driving force behind tumor angiogenesis. The stabilization and activation at hypoxia of the hypoxia-inducible factors HIF-1α and HIF-2α and the concomitant induction of expression of vascular endothelial growth factor (VEGF) and other proangiogenic factors provide a molecular frame for hypoxia-driven tumor angiogenesis. This study has investigated how HIF and VEGF protein levels relate to each other with regard to vascularization, tumor stage, and overall survival in neuroblastoma. Experimental Design: Tissue cores taken from tumor specimens representing 93 children with neuroblastoma were arranged on a microarray and stained for HIF-1α,…

MaleVascular Endothelial Growth Factor ACD31Cancer ResearchPathologymedicine.medical_specialtyBiologyModels BiologicalNeovascularizationchemistry.chemical_compoundIn vivoNeoplasmsNeuroblastomaBasic Helix-Loop-Helix Transcription FactorsmedicineHumansHypoxiaRegulation of gene expressionNeovascularization PathologicInfantCancerHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseGene Expression Regulation NeoplasticPlatelet Endothelial Cell Adhesion Molecule-1Vascular endothelial growth factorTreatment OutcomeHIF1AOncologychemistryChild PreschoolCancer researchFemalemedicine.symptomClinical Cancer Research
researchProduct

Angiogenesis in Wounds Treated by Microdeformational Wound Therapy.

2011

BACKGROUND:: Mechanical forces play an important role in tissue neovascularization and are a constituent part of modern wound therapies. The mechanisms by which vacuum assisted closure (VAC) modulates wound angiogenesis are still largely unknown. OBJECTIVE:: To investigate how VAC treatment affects wound hypoxia and related profiles of angiogenic factors as well as to identify the anatomical characteristics of the resultant, newly formed vessels. METHODS:: Wound neovascularization was evaluated by morphometric analysis of CD31-stained wound cross-sections as well as by corrosion casting analysis. Wound hypoxia and mRNA expression of HIF-1α and associated angiogenic factors were evaluated by…

MaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyWound therapyAngiogenesismedicine.medical_treatmentNeovascularization PhysiologicOcclusive DressingsArticleNeovascularizationMiceNegative-pressure wound therapymedicineAnimalsSkinWound Healingintegumentary systemReverse Transcriptase Polymerase Chain Reactionbusiness.industryGranulation tissueBiomechanical PhenomenaMice Inbred C57BLOxygenPlatelet Endothelial Cell Adhesion Molecule-1Occlusive dressingVascular endothelial growth factor Amedicine.anatomical_structureMicrovesselsGranulation TissueCancer researchSurgerymedicine.symptombusinessWound healingNegative-Pressure Wound Therapy
researchProduct

Characterization of New Organic Nitrate Hybrid Drugs Covalently Bound to Valsartan and Cilostazol

2012

Background and Purpose: Organic nitrates represent a group of nitrovasodilators that are clinically used for the treatment of ischemic heart disease. With the present studies we synthesized and characterized new organic nitrate hybrid molecules. Compounds CLC-1265 (valsartan mononitrate) and CLC-1280 (valsartan dinitrate) are derivatives of the angiotensin receptor blocker valsartan, with CLC-1265 containing a single organic nitrate linker and CLC-1280 also containing a second, different linker. Compounds CLC-2000 (cilostazol mononitrate) and CLC-2100 (cilostazol dinitrate) are nitrate derivatives of the phosphodiesterase III inhibitor cilostazol. All compounds are designed as hybrid molecu…

MaleVasodilator AgentsTetrazoleschemistry.chemical_elementmedicine.disease_causeOxygenchemistry.chemical_compoundNitratemedicineAnimalsOrganic chemistryRats WistarPharmacologyNitratesValineGeneral MedicineIn vitroCilostazolRatsCilostazolOxidative StressValsartanchemistryVasoconstrictionCovalent bondValsartanLinkerPlatelet Aggregation InhibitorsOxidative stressmedicine.drugPharmacology
researchProduct

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention …

2019

Background: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI. Methods: Using a 2×2 factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y 12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: patients with ACS treated medically, patients with ACS treated with PCI,…

MaleVitamin Kmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicineAntithromboticAtrial Fibrillation//purl.org/pe-repo/ocde/ford#3.02.04 [https]030212 general & internal medicineProspective Studies610 Medicine & healthAspirinVKADisease ManagementAtrial fibrillationVitamin K antagonistMiddle AgedCombined Modality TherapyHospitalizationTreatment Outcomesurgical procedures operativeElective Surgical ProceduresCardiologyApixabanDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyAcute coronary syndromemedicine.drug_classPyridonesDOACHemorrhageP2Y12 inhibitor03 medical and health sciencesPercutaneous Coronary InterventionFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeAgedProportional Hazards ModelsAspirinbusiness.industryPercutaneous coronary interventionAnticoagulantsCardiovascular Agentsmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsPyrazolesbusinessPlatelet Aggregation Inhibitors
researchProduct

Perioperative risk of bleeding with antithrombotic agents in macular surgery: a national, prospective, multicentre study

2020

International audience; Purpose To compare the risk of haemorrhagic complications in elective macular surgery between patients with no antithrombotic (AT) treatment (defined as patients with no history of AT therapy or who discontinued AT therapy) and patients who continued AT treatment during the surgery. Methods E-case report forms were prospectively recorded in a database before vitreoretinal surgery and 1 month after. Data on patient characteristics, surgical techniques, haemorrhagic complications and antithrombotic status were collected. Patients with retinal detachment, proliferative diabetic retinopathy and previous retinal haemorrhage were excluded. Results A total of 748 procedures…

Male[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologynoncardiac surgeryantiplateletsurgery0302 clinical medicineRisk FactorsAntithromboticMedicineProspective Studiesoral anticoagulantsguidelinesantithrombotic agenteducation.field_of_studyAnticoagulantvitreoretinalRetinal HemorrhageGeneral MedicineDiabetic retinopathy3. Good healthPopulation SurveillanceFemalemacular surgeryhaemorrhagehemorrhagemanagementmedicine.medical_specialtymedicine.drug_classPopulationPostoperative Hemorrhagemaintenance03 medical and health sciencesHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganseducationAgedbusiness.industryanticoagulantAnticoagulantsPerioperativeOdds ratioRetinal Perforationsmedicine.diseasedual antiplatelet therapyvitreoretinal surgeryConfidence intervalSurgerywarfarinOphthalmology030221 ophthalmology & optometrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up StudiesRetinal haemorrhage
researchProduct

Two new cases of Thrombocytopenia Absent Radius (TAR) syndrome: Clinical, Genetic and Nosologic Features

1988

Two unrelated children affected by TAR syndrome, autosomic recessive disease with congenital thrombocytopenia and bilateral radial aplasia, are described. In the first case a mild thrombocytopenia has been compatible with a fairly normal life until the second year of age. The other child shows radial aplasia associated with other anomalies of the upper limbs, severe thrombocytopenia and leukemoid reaction. The relationship among TAR syndrome, Fanconi's anemia and Roberts' syndrome are briefly discussed.

Malecongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyEctromeliaAnemiaChromosome DisordersGenes RecessiveRadial aplasiaBiologyConsanguinityBilateral radial aplasiahemic and lymphatic diseasesmedicineClinical geneticHumansAbnormalities MultipleChromosome AberrationsPlatelet CountTAR syndromeInfantSyndromemedicine.diseaseThrombocytopeniaDermatologySevere thrombocytopeniaRadiusPediatrics Perinatology and Child HealthFemaleAbsent radiusLeukemoid reactionKlinische Pädiatrie
researchProduct

Does the NO/sGC/cGMP/PKG pathway play a stimulatory role in platelets?

2012

Nitric oxide (NO) stimulates cGMP synthesis by activating its intracellular receptor, soluble guanylyl cyclase (sGC). It is a currently prevailing concept that No and cGMP inhibits platelet function. However, the data supporting the inhibitory role of NO/sGC/cGMP in platelets have been obtained either in vitro or using whole body gene deletion that affects vessel wall function. Here we have generated mice with sGC gene deleted only in megakaryocytes and platelets. Using the megakaryocyte- and platelet-specific sGC-deficient mice, we identify a stimulatory role of sGC in platelet activation and in thrombosis in vivo. Deletion of sGC in platelets abolished cGMP production induced by either NO…

Maleinorganic chemicalsbusiness.industryImmunologyReceptors Cytoplasmic and NuclearCell BiologyHematologyPlatelet ActivationPlatelets and ThrombopoiesisBiochemistryCell biologyCyclic gmpGuanylate Cyclasecardiovascular systemAnimalsMedicineFemaleheterocyclic compoundsPlateletbusinessSoluble guanylyl cyclaseBlood
researchProduct

''Circulating and Brain BDNF Levels in Stroke Rats. Relevance to Clinical Studies''

2011

International audience; ''Background: Whereas brain-derived neurotrophic factor (BDNF) levels are measured in the brain in animal models of stroke, neurotrophin levels in stroke patients are measured in plasma or serum samples. The present study was designed to investigate the meaning of circulating BDNF levels in stroke patients. Methods and Results: Unilateral ischemic stroke was induced in rats by the injection of various numbers of microspheres into the carotid circulation in order to mimic the different degrees of stroke severity observed in stroke patients. Blood was serially collected from the jugular vein before and after (4 h, 24 h and 8 d) embolization and the whole brains were co…

Malelcsh:MedicineEDEMA''CardiovascularBiochemistry0302 clinical medicineNeurotrophic factorsJugular veinEdemaBlood plasmaNeurobiology of Disease and RegenerationMedicineHippocampus (mythology)Plateletlcsh:ScienceStroke0303 health sciencesMultidisciplinary''NEUROTROPHIC FACTORbiologyBrainNeurochemistryAnimal ModelsRECOVERYDEPRESSIONPLATELETSStrokeISCHEMIC-STROKENeurologyOrgan SpecificityAnesthesia[ SCCO.NEUR ] Cognitive science/NeuroscienceMedicinemedicine.symptomNeurotrophinResearch Articlemedicine.medical_specialtyCerebrovascular DiseasesImmunologyMETABOLISM03 medical and health sciencesModel OrganismsInternal medicineAnimalsHumanscardiovascular diseasesRats WistarImmunoassaysBiology030304 developmental biologyIschemic Strokebusiness.industryBrain-Derived Neurotrophic Factor[SCCO.NEUR]Cognitive science/Neurosciencelcsh:REDEMAmedicine.diseaseENDOTHELIAL-CELLSRatsEndocrinologynervous systemMARKERbiology.proteinImmunologic TechniquesRatlcsh:QClinical Immunologybusiness030217 neurology & neurosurgeryNeuroscienceNEUROTROPHIC FACTOR
researchProduct

Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina

2006

SummaryApplication of clopidogrel before percutaneous coronary intervention in patients with acute coronary syndrome reduces the risk of cardiac events. Clopidogrel administration before surgery increases bleeding complications after CABG. Therefore, the antithrombotic effect of the low-dose combination of clopidogrel and aspirin was investigated in an in vivo pig model of coronary artery thrombus formation with cyclic flow reductions. The platelet inhibitory effect was determined by platelet aggregation and CFR, according to the methodology described by Folts. CFR were initiated by endothelial damage and placement of a constrictor around the LAD. 30 min after CFR were established, clopidog…

Malemedicine.medical_specialtyAcute coronary syndromeTiclopidinePlatelet AggregationSwinemedicine.medical_treatmentAnginaInternal medicineAntithromboticmedicineAnimalsPlateletAngina Unstablecardiovascular diseasesAspirinAspirinbusiness.industryUnstable anginaCoronary ThrombosisPercutaneous coronary interventionHematologymedicine.diseaseClopidogrelClopidogrelDisease Models AnimalAcute DiseaseCardiologyDrug Therapy CombinationbusinessPlatelet Aggregation Inhibitorscirculatory and respiratory physiologymedicine.drugThrombosis and Haemostasis
researchProduct

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

2019

Background: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. Methods: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. Results: Enroll…

Malemedicine.medical_specialtyAcute coronary syndromeVitamin KPyridonesmedicine.medical_treatmentMEDLINEHemorrhage030204 cardiovascular system & hematologylaw.invention03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicinePharmacotherapyDouble-Blind MethodRandomized controlled triallawInternal medicineAtrial FibrillationAntithromboticmedicineHumans03.02. Klinikai orvostancardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedAged 80 and overAspirinbusiness.industryatrial fibrillation ; anticoagulant therapy ; acute coronary syndrome ; apixabanAnticoagulantsPercutaneous coronary interventionAtrial fibrillationGeneral MedicineMiddle Agedmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsCardiologyPyrazolesDrug Therapy CombinationFemalebusinessPlatelet Aggregation InhibitorsFactor Xa InhibitorsNew England Journal of Medicine
researchProduct